Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus Abiraterone vs Abiraterone in mCRPC
NCT01685125Phase 2Unknown
- Sponsor
- University of Southern California
- Start
- Sep 2012
- Primary completion
- Mar 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Southern California. Status: unknown.
02
Drugs
dasatinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01685125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685125.